ArticleJournal of endocrinological investigation2026
Morning cortisol and central adrenal insufficiency: new thresholds from low-dose ACTH test and second-generation assay.
Article in Journal of endocrinological investigation, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeAccording to current guidelines, a morning serum cortisol < 30 µg/L confirms central adrenal insufficiency (CAI), whereas a value > 150 µg/L rules it out. However, these thresholds are based on older assays, and intermediate values require further testing. Newer, specific monoclonal antibody immunoassays may have lower diagnostic thresholds. This study aimed to identify morning cortisol cut-offs with ≥ 95% specificity or sensitivity (SP/SE) to determine which patients may safely avoid ACTH stimulation testing, using a second-generation immunoassay.
methodsWe retrospectively evaluated 435 adults (236 males; overall median age 58.5 [IQR 20.3] years) with pituitary disorders. Based on the 1 µg ACTH test, patients were classified as having or not having CAI using a peak cortisol cut-off of 180 µg/L (guideline) or 127 µg/L (Roche Elecsys® Cortisol II–based studies).
resultsWith the 180 µg/L threshold, a morning cortisol ≤ 80.8 µg/L best predicted CAI (SE 37.1%, SP 95.2%), while > 144.0 µg/L best excluded it (SE 95.2%, SP 29.1%). Using the 127 µg/L threshold, a value ≤ 60.9 µg/L best predicted CAI (SE 54.7%, SP 96.3%), whereas > 141 µg/L (SE 96.2%, SP 21.2%) best ruled it out.
conclusionsWe identified updated morning cortisol thresholds, specific to a second-generation immunoassay, that accurately predict ACTH test results and may streamline the diagnostic workup of suspected CAI. Based on these data, we propose a refined diagnostic algorithm.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.